All In Biotech

Drug Trial Radar · NCT00291642

A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen

Double Blind, Double-dummy, Five Parallel Groups, Randomized, Exploratory Clinical Trial to Compare the Efficacy of Single Dose of Levocetirizine 2.5 mg Oral Drops (5 mg/mL), Levocetirizine 5 mg Oral Tablets, Cetirizine 5 mg Oral Drops (10 mg/mL) and Cetirizine 10 mg Oral Tablets to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Ragweed Sensitive Subjects Exposed to Ragweed Pollen in an Environmental Exposure Unit (EEU)

Last checked: Nov 20, 2026Latest source record: Sep 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 551 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

551

Actual

Start

Jan 1, 2006

Primary completion

Apr 1, 2006

Study completion Apr 1, 2006

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Feb 14, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the efficacy comparability of cetirizine and levocetirizine, by comparing the effects of single intake of the two drugs to placebo in reducing symptoms of seasonal allergic rhinitis (SAR) in ragweed sensitive adult subjects exposed to ragweed pollen in an Environmental Exposure Unit.

Conditions

  • Rhinitis
  • Allergic
  • Seasonal

Interventions

  • Placebo dropsDrug

    * Pharmaceutical form: Drops for oral administration * Route of administration: Oral use

  • Placebo tablets matching to levocetirizineDrug

    * Pharmaceutical form: Tablets for oral administration * Route of administration: Oral use

  • Placebo tablets matching to cetirizineDrug

    * Pharmaceutical form: Tablets for oral administration * Route of administration: Oral use

  • Levocetirizine dropsDrug

    * Pharmaceutical form: Drops for oral administration * Concentration: 5 mg/ml * Route of administration: Oral use

  • Levocetirizine tabletsDrug

    * Pharmaceutical form: Tablets for oral administration * Concentration: 5 mg * Route of administration: Oral use

  • Cetirizine dropsDrug

    * Pharmaceutical form: Drops for oral administration * Concentration: 10 mg/ml * Route of administration: Oral use

  • Cetirizine tabletsDrug

    * Pharmaceutical form: Tablets for oral administration * Concentration: 10 mg * Route of administration: Oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Major Symptom Complex (MSC) Score Over Period ITime frame: Baseline, Treatment Period 1 [Day 1, from drug intake (at 11:00 am) to 5 hours post-treatment (at 4:00 pm)]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Kingston, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.